We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 small molecule which complements and strengthens our growing portfolio of novel candidates for treating obesity and its adjacent diseases" Dr Chris Boshoff, PhD, Chief Scientific Officer and President, Research & Development at Pfizer, said: We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 small molecule which complements and strengthens our growing portfolio of novel candidates for treating obesity and its adjacent diseases
, ,
PlexusDx serves all 50 states with no insurance required, HSA/FSA eligibility, and flat monthly pricing (your dose may change, but your price stays the same)
This protocol is standard within our endocrinology service and is routinely practiced, both within the scope of this study and as part of routine clinical care
Potential for gastrointestinal blockage: Because Ozempic slows gut motility, theres a theoretical risk it could exacerbate conditions like gastroparesis (slow stomach emptying) or even bowel obstruction in susceptible individuals
Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: scandinavian cohort study